Roche's Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Receives FDA's Approval for Patients with HER2-Positive Breast Cancers
Shots:
- The approval is based on three P-III study (HannaH- SafeHER- PrefHER) results assessing Herceptin Hylecta (SC) + CT vs Herceptin (IV) + CT in neoadjuvant and adjuvant patients with HER2-positive early breast cancer
- P-III HannaH- SafeHER- PrefHER study: pCR (absence of invasive cancer cells in breast) (45.4% vs 40.7%); mean level of trastuzumab (78.7mcg/ml vs 57mcg/ml); no new safety signals- tolerable
- Herceptin Hylecta (trastuzumab and hyaluronidase-oysk- SC) based on Halozyme’s Enhanze drug delivery technology targeted for patients with HER2-positive early breast cancer
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com